In the PyVT mouse model, Rlip knockout did not delay oncogenesis or tumor growth, and Rlip knockdown did not regress PyVT-driven mammary tumors, suggesting that Rlip inhibition strategies may be inappropriate in the prevention or treatment of breast cancer in patients with SV40 infections or with tumors positive for polyomavirus DNA, respectively. Here, RALBP1 is linked to breast carcinoma.